Previous 10 | Next 10 |
Shares of the clinical-stage cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) were down by 9.1% as of 2:37 p.m. ET on Wednesday. Earlier today, the biotech's shares were down by an unsightly 12.5% at their low point. Investors appear to be throwing in the towel o...
November has been brutal for biotech stocks. The SPDR S&P Biotech ETF has dropped by 5.1% just 2 1/2 weeks into the month. This bellwether biotech exchange-traded fund (ETF), in turn, has now declined by a hefty 12.7% so far this year. While no single culprit can be fingered as the ...
- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests that addition of AKT inhibitor (AKTi) during manufacture can remodel gene express...
Adaptimmune Therapeutics (ADAP -0.5%) announced that its ongoing SPEARHEAD-1 trial for afami-cel in advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) would meet the primary endpoint based on the overall response rate (ORR). The company is on track to report updated data ...
- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - - The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rat...
Image source: The Motley Fool. Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q3 2021 Earnings Call Nov 4, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Trans...
Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Conference Call November 4, 2021 08:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer John Lunger - Chief Patient Supply Officer Helen Tayton-Martin - Co-Founder and Chi...
Adaptimmune (NASDAQ:ADAP): Q3 GAAP EPS of -$0.05 beats by $0.21. Revenue of $1.2M (+0.8% Y/Y) beats by $0.26M. Press Release Financial Guidance: The Company believes that its existing cash, cash equivalents and marketable securities, together with the upfront and exclusivity payments under th...
- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - - SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tumors: overall response rate of 36%...
Adaptimmune (NASDAQ:ADAP) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $0.94M (-21.0% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downwa...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...